Highland Capital Management (Texas)’s Sarepta Therapeutics SRPT Stock Holding History

Highland Capital Management (Texas)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-4,000	Closed	-$529K	–	355
2018 Q2	$529K	Buy	+4,000	New	+$377K	0.03%	202
2017 Q1	–	Sell	-85,600	Closed	-$2.35M	–	319
2016 Q4	$2.35M	Buy	+85,600	New	+$3.44M	0.11%	135
2016 Q1	–	Sell	-116,152	Closed	-$4.48M	–	270
2015 Q4	$4.48M	Sell	116,152 -268,309	-70%	-$8.7M	0.14%	143
2015 Q3	$12.3M	Buy	384,461 +52,552	+16%	+$1.78M	0.36%	83
2015 Q2	$10.1M	Buy	331,909 +103,085	+45%	+$2.11M	0.21%	113
2015 Q1	$3.04M	Hold	228,824	–	–	0.06%	163
2014 Q4	$3.31M	Sell	228,824 -24,588	-10%	-$416K	0.11%	120
2014 Q3	$5.35M	Buy	253,412 +193,486	+323%	+$4.37M	0.2%	106
2014 Q2	$1.78M	Sell	59,926 -121,590	-67%	-$3.84M	0.07%	144
2014 Q1	$4.36M	Buy	181,516 +112,202	+162%	+$2.86M	0.17%	97
2013 Q4	$1.41M	Buy	+69,314	New	+$2.06M	0.08%	92

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Highland Capital Management (Texas)'s SRPT Position: Q3 2018 in Review

Highland Capital Management (Texas) sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 4,000 shares — an estimated $529K sold.

Highland Capital Management (Texas) first reported a position in SRPT in Q4 2013 and held it in 11 quarters. The position peaked at $12.3M in Q3 2015. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

Highland Capital Management (Texas) reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
Highland Capital Management (Texas) sold 4,000 Sarepta Therapeutics shares in Q3 2018, an estimated $529K.
Highland Capital Management (Texas) first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 11 quarters.
Highland Capital Management (Texas)'s Sarepta Therapeutics position peaked at $12.3M in Q3 2015.
344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Highland Capital Management (Texas)'s 13F filing for Q3 2018, filed 14 Nov 2018.